Abstract 4094
Background
In pediatric patients (pts) with localized osteosarcoma, cure rates higher than 60% have been reported. A chemotherapy (CT) regimen frequently suggested as standard in this scenario is the three-drug regimen MAP (methotrexate [MTX], doxorubicin, and cisplatin). However, the addition of MTX remains controversial, especially in adult pts in whom high-grade toxicities are frequent. We aimed to evaluate the outcomes of adult pts with localized osteosarcoma after treatment with CT without MTX.
Methods
A single-center cohort of adult pts with high-grade osteosarcoma treated with CT without MTX was retrospectively evaluated. Pts were treated between 2007 and 2018. Overall survival (OS) was calculated from the date of diagnosis to death. Recurrence-free survival (RFS) was time from diagnosis to recurrence or death. Kaplan-Meier method was used for survival analysis. Prognostic factors were evaluated with Cox regression.
Results
A total of 97 consecutive adult pts with osteosarcoma were studied. Median age was 27 years (range 16 – 69). Primary tumor site was extremity in 79.4% of pts (N = 77), and axial in 20.6% (N = 20). Most pts (N = 61; 63%) presented localized resectable disease, while 36 (37%) had unresectable or metastatic disease. Among pts with localized resectable disease, 56 (91%) pts received neoadjuvant/ adjuvant CT without MTX: 48 (86%) received cisplatin and doxorubicin; 8 (14%) received other combinations of cisplatin, doxorubicin, ifosfamide, and/or etoposide. With a median follow-up of 34 months, 3-year and 5-year RFS rates were 42.4% (IC 95% 28 – 55%) and 37.1% (IC 95% 23 – 50%). 3-year and 5-year OS rates were 81.6% (95% CI, 67% – 90%) and 67.3% (95% CI, 48% – 80%). Median RFS and OS were 31.8 months and not reached, respectively. The only factor associated with OS was the number of neoadjuvant/ adjuvant CT cycles (≥ 6 vs < 6 cycles: HR 0.25, 95% CI 0.07 – 0.83, P = 0.025).
Conclusions
Adult pts with localized osteosarcoma treated with CT without MTX had unfavorable survival outcomes in comparison with the literature for pediatric pts. A number of neoadjuvant/ adjuvant CT cycles of 6 or more was associated with superior OS. Improving therapeutic approaches for adult pts is of utmost importance to achieve better results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757 - Development of chimeric antigenic receptor (CAR) against VEGFR2 for solid tumor treatment
Presenter: Li-Shuang Ai
Session: Poster Display session 1
Resources:
Abstract
4156 - Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells.
Presenter: Nunzia Matrone
Session: Poster Display session 1
Resources:
Abstract
2949 - EGFR-mediated PD-L1 upregulation in HER2+ breast cancer (BC) cell line models
Presenter: Nicola Gaynor
Session: Poster Display session 1
Resources:
Abstract
4270 - The impact of cortisol on immune cells and its effect on cancer-immune cells co-culture in a 3D spheroid of ovarian cancer
Presenter: Maysa Al-natsheh
Session: Poster Display session 1
Resources:
Abstract
1568 - Application of sonoporation to increase anticancer drug efficacy in 2D and 3D NSCLC cell cultures
Presenter: Vilma Petrikaite
Session: Poster Display session 1
Resources:
Abstract
5400 - Tr1-like cells in human peripheral blood are part of the T effector memory pool and are preferentially stimulated via CD55
Presenter: Iniobong Charles
Session: Poster Display session 1
Resources:
Abstract
5817 - Functional analysis of tumor infiltrating lymphocytes in triple negative breast cancer focusing on granzyme B
Presenter: Hitomi Kawaji
Session: Poster Display session 1
Resources:
Abstract
2287 - Aberrant glycolysis associates with inflammatory tumor microenvironment and promotes metastasis in triple-negative breast cancer
Presenter: Chengwei Lin
Session: Poster Display session 1
Resources:
Abstract
735 - Anti-cancer effects of differentiation-inducing factor-1 in triple negative breast cancer.
Presenter: Fumi Tetsuo
Session: Poster Display session 1
Resources:
Abstract
2105 - The Inhibitory Effect in Oral Squamous Cell Carcinoma Cells by Knocking down Matrix Metalloproteinase 9
Presenter: Xinyan Zhang
Session: Poster Display session 1
Resources:
Abstract